Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

30 October 2019

Download Full Press Release

PDF Download

 

Trading in the third quarter for Convatec Group Plc (“the Group”), a leading global medical products and technologies company, was in-line with management expectations and full year guidance remains unchanged.

 

Key Points:

  • Group revenue for the three months to 30 September 2019 was $462.9 million, 2.4% higher on a reported basis and 4.6%1 higher on an organic basis compared with the prior year, in part reflecting the benefits of some short-term tailwinds. For the 9 months to 30 September 2019 revenue was $1,351.8 million, a decline of 1.6% on a reported basis due to foreign exchange movements, but growth of 1.5%1 on an organic basis, compared with the prior year.
  • Franchise Q3 summary:
    • Advanced Wound Care: organic growth of 3.6%1 was driven by our silver portfolio, in particular AQUACELTM Ag+, and foam, whilst distributor inventory movements provided a short-term tailwind which will partly reverse in Q4;
    • Ostomy Care: organic growth of 3.0%1 reflected a solid underlying performance against a weak 2018 performance;
    • Continence and Critical Care: organic growth of 8.0%1 was flattered, as expected, by a weaker prior year comparator due to the packaging recall, along with continued growth in our Home Distribution Group (HDG);
    • Infusion Devices: organic growth of 4.3%1 reflected a weaker prior year comparator.
  • Transformation Initiative on track.
  • FY 2019 guidance unchanged.

 

 

Karim Bitar, Chief Executive Officer, commented:

“I am excited to have joined Convatec and returned to the healthcare sector. Since I joined the Group at the end of September I have had the opportunity to visit several sites and engage with many colleagues; I have been encouraged by their enthusiasm and the potential within Convatec.

I am pleased we have reported a solid performance in Q3, but this is a small step on the significant journey ahead of us as we focus on pivoting to sustainable and profitable growth. As an organisation we need to get closer to patients, to strengthen our innovation pipeline and to drive a relentless focus on execution excellence.

I look forward to giving an update on our plans and progress next year.”

Group revenue

Group revenue of $462.9 million grew 4.6%1 on an organic basis in Q3, compared with the prior year. Due to unfavourable foreign exchange movements, on a reported basis Group revenue grew 2.4%. 

For the 9 months to 30 September 2019 Group revenue was $1,351.8 million, a decline of 1.6% on a reported basis, again due to unfavourable foreign exchange, but growth of 1.5%1 on an organic basis. 

In Advanced Wound Care, revenue of $147.5 million increased 3.6%1 on an organic basis in Q3, a decent performance driven by our silver portfolio, in particular AQUACELTM Ag+, and foam. A number of markets in EMEA and Latin America performed well, while we continued to focus on leveraging our specialised and expanded salesforce in the US. There were some distributor inventory movements in the current and prior year which provided a tailwind in the quarter, which we anticipate will partly reverse in Q4. 

In Ostomy Care, revenue of $131.7 million grew by 3.0%1 on an organic basis in Q3, a solid underlying performance albeit set against a weaker performance in 2018. The quarter also benefitted from the timing of a tender in Latin America. 

In Continence & Critical Care, revenue of $115.1 million grew by 8.0%1 on an organic basis in Q3, driven by a good performance in Continence Care, primarily HDG. Critical and Hospital Care benefitted from a weaker prior year comparator, a result of the packaging recall which was instigated in the third quarter of last year, reducing the drag on growth from these businesses in the quarter. 

In Infusion Devices revenue of $68.6 million increased 4.3%1 year on year on an organic basis in Q3, driven by a good level of customer orders and a weaker prior year comparator.

The Transformation Initiative remains on track as we continue to implement the improvement projects and we will provide an update on progress with the FY19 results.

On 24 October 2019 the Group successfully completed a refinancing of the debt put in place at the time of the IPO in October 2016. The debt outstanding under this arrangement of approx. $1.6 billion term debt and an undrawn $200 million revolving credit facility has been replaced with a committed 5-year bank facility of a $1.5 billion term debt and a $200 million revolving credit facility, on more favourable terms overall.

As announced on 19 August, Dr. John McAdam has been appointed as Chairman of the Board and he assumed his position on 30 September 2019.

 

Outlook and guidance

The outlook for the Group for FY 2019 is unchanged:

  • Organic revenue growth of 1.0% to 2.5%1
  • Adjusted EBIT margin 18% to 20%, including spend associated with the Transformation Initiative and Medical Device Regulation (MDR). Excluding these costs, adjusted EBIT margin is expected to be 21.0% to 22.5%.

(...)

Download the full text of this announcement

PDF Download

 

Enquiries

Analysts and Investors 

investorrelations@convatec.com

John Crosse, VP Investor Relations

+44 (0)7500 141435

Mark Reynolds, Director Investor Relations

+44 (0)7551 036625

Media

convatec@buchanan.uk.com

Buchanan

Charles Ryland/Chris Lane/Vicky Hayns

+44 (0)207 4665000

 

 

 

Press Release

See all

5/13/2022

5/13/2022

Convatec Group Plc Annual Results 2018

Convatec Group Plc Annual Results 2018

Read more

5/13/2022

5/13/2022

2018 Annual Report & Accounts

2018 Annual Report & Accounts

Read more

5/13/2022

5/13/2022

Appointment of Chief Executive Officer

Appointment of Chief Executive Officer

Read more

5/13/2022

5/13/2022

Board Changes

Board Changes

Read more

5/13/2022

5/13/2022

Results of Annual General Meeting

Results of Annual General Meeting

Read more

5/13/2022

5/13/2022

Convatec partners with EWMA to support Research Grants in 2019

Convatec partners with EWMA to support Research Grants in 2019

Read more

5/13/2022

5/13/2022

Board Change

Board Change

Read more

5/13/2022

5/13/2022

Beta Bionics and Convatec announce partnership to bring Unomedical infusion set portfolio to the iLet™ Bionic Pancreas System

Beta Bionics and Convatec announce partnership to bring Unomedical infusion set portfolio to the iLet™ Bionic Pancreas System

Read more

5/13/2022

5/13/2022

Convatec Group Plc First Half Results 2019

Convatec Group Plc First Half Results 2019

Read more

5/13/2022

5/13/2022

John McAdam appointed Chairman of Convatec

John McAdam appointed Chairman of Convatec

Read more

5/13/2022

5/13/2022

Acquisition of Southlake Medical Supplies

Acquisition of Southlake Medical Supplies

Read more

5/13/2022

5/13/2022

Trading Update for the three months ended 30 September 2019

Trading Update for the three months ended 30 September 2019

Read more